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Abstract
Introduction:  ETS-1 proto-oncogene is a transcription factor that plays multiple roles in the process of
oncogenesis and helps in the process of tumor invasion. ETS-1 oncoprotein correlation with high grade
and invasive tumors is controversial; as it is found to be upregulated with some tumors and down regulated
with others. Expression of ETS-1 in urinary bladder carcinoma (UBC) and its correlation with tumor
differentiation and invasiveness are still under-investigated. So far, there is no reliable prognostic marker
has been proved for detection of the tumor progression and recurrence.
Objectives:  To analyze the correlation between ETS-1 oncoprotein immunohistochemical expression and
the different stages and grades of the primary papillary transitional cell carcinoma of the urinary bladder.
Patients and  methods:  This is a retrospective cross sectional study that included archival material from 150
cancer cases and 24 control biopsies.
Results:  There was a decreased ETS-1 oncoprotein expression with increasing stage and grade of the
tumor with a highly significant statistical correlation (P  = 0.001). With the quantitative assessment of the
immunohistochemical results and using ROC (receiver operating characteristics) curve, cut-off values were
found, that were associated with high grade and muscle invasive tumors (≤30% and ≤20%, respectively).Please cite this article in press as: Ibrahim EA, et al. ETS-1 oncoprotein expression is decreased in aggressive papillary transitional cell
carcinoma of the urinary bladder: An immunohistochemical study. Afr J Urol (2016), http://dx.doi.org/10.1016/j.afju.2015.10.007
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Conclusion:  ETS-1 oncoprotein is down regulated with high grade and highly invasive urinary bladder
papillary transitional cell carcinomas. This oncoprotein may be used as an independent prognostic marker
to predict the aggressive papillary transitional carcinomas with high invasive potential. More studies are
needed to confirm our results.
© 2016 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rinary bladder carcinoma (UBC) is one of the most prevalent
alignant tumors worldwide; it is the ninth in incidence order
mongst others. It is the seventh most common malignancy in adult
ales and the 17th among adult females [1,2].
TS-1 proto-oncogene is a transcription factor that plays multiple
oles in the process of oncogenesis. It helps the process of tumor
nvasion by modulating the extracellular matrix via stimulating the
ranscription of metalloproteinases and urokinase-type plasminogen
ctivator [3]. Furthermore, it activates the endothelial cells prolif-
ration and activation, thus stimulating the angiogenesis and tumor
rogression [4]. ETS-1 oncoprotein correlation with high grade and
nvasive tumors is found to be controversial; as it is found to be
pregulated with some tumors [5–10] and down regulated with oth-
rs [11–13]. This can be explained by the different target proteins
hich may result in a competitive function that may be expressed
ifferently in various organs [13].
xpression of ETS-1 in UBC and its correlation with the tumor
ifferentiation and invasiveness are still under-investigated.
bjectives
he present study aims to evaluate the significance of ETS-1
xpression in papillary transitional cell carcinoma of the urinary
ladder and determine the relationship of this oncoprotein with the
istopathological parameters including tumor grade and stage.
ubjects  and  methods
his is a retrospective cross sectional study performed in the
athology department of Ain Shams Specialized University Hos-
ital (ASUSH). The studied material comprised of archival paraffin
locks of urinary bladder papillary transitional cell carcinoma from
atients who underwent radical cystectomy or TURT. The control
ases consisted of cystoscopic biopsies for chronic cystitis, in an
nonymous way, so no consent was needed from the patients. The
esearch study was approved by the Research Ethical Committee of
in Shams University, the rules of which were in accordance with
he ethical standards laid down in 1964 Declaration of Helsinki.
pecimen  and  data  collection
e retrieved 157 cases of primary papillary transitional cell carci-Please cite this article in press as: Ibrahim EA, et al. ETS-1 oncoprotei
carcinoma of the urinary bladder: An immunohistochemical study. Afr
oma of the urinary bladder and 24 control biopsies. Paraffin blocks
ere retrieved from the pathology departments of ASUSH and Alde-
erdash Hospital in the period from January 2010 to December
014. Archival files of the cases were also retrieved and all
g
c
C
qvailable clinical data were registered (age, sex and stage of the
umor). Inclusion criteria included a diagnosis of primary uri-
ary bladder papillary transitional cell carcinoma, with availability
f adequate clinical data and the presence of, furthermore, ade-
uately presented muscularis propria for proper assessment of the
umor invasion. Exclusion criteria included inadequate clinical data,
umors with much tissue necrosis and absence of muscularis propria
n the examined sections.
e excluded five cases due to inadequate clinical history and another
wo cases due to extensive tumor tissue necrosis. Of the remaining
ere 150 cases, for the study; there were 81 cases had undergone
adical cystectomy and the remaining 69 were transurethral biopsies.
istopathological  examination
he slides of the selected cases were reviewed under light
icroscopy. The tumors were graded according to the World Health
rganization 2004 system [14] and staged into: stages 0 and I (early
ladder cancer), stages II and III (invasive bladder cancer) and stage
V (advanced bladder cancer) [15].
mmunohistochemical  staining  and  scoring
our micron-thick sections were cut from the selected paraf-
n blocks and stained immunohistochemically by using ETS-1
ntibody (mouse monoclonal antibody) (Clone 1G11: Cat. #MS-
762-R7) (7.0 ml) (Thermo Fisher Scientific Inc, MA, USA). It was
 ready-to-use reagent; the manufacturer’s staining protocol was
ollowed. For positive control we used human tonsillar tissue and
mitting the use of primary antibody was done for negative controls
o ensure correct staining procedure [16].
TS-1 expression was assessed semi-quantitatively into 3 categories
ccording to the percentage of cells with positive nuclear staining;
he results were expressed as follows: score 0 = 0–10% positive cells;
core 1 = 10–50% positive cells; score 2 = >50% positive cells [17].
tatistical  analysis
he collected data was revised, coded, tabulated and introduced
o a PC using Statistical package for Social Science (SPSS 15.0.1
or windows; SPSS Inc., Chicago, IL, 2001). Data was presented
nd suitable analysis was done; Mean, Standard deviation (±SD)
nd range for parametric numerical data, Student’s t-test to assess
he statistical significance of the difference between two studyn expression is decreased in aggressive papillary transitional cell
 J Urol (2016), http://dx.doi.org/10.1016/j.afju.2015.10.007
roup means, ANOVA test was used to assess the statistical signifi-
ance of the difference between more than two study group means.
hi-square test was used to examine the relationship between two
ualitative variables. Fisher’s exact test was done to examine the
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Table  1  Correlation between the patients’ demographic data and their clinicopathologic features.
Parameter Age Sex Total
Mean ± SD Male Female (100%)
Tumor stage
0 (9) 50.7 ± 11.8 9 (7.7%) 0 (0%) 6%
I (54) 56.9 ± 13.9 39 (33.3%) 15 (45.5%) 36%
II (38) 58.6 ± 13 28 (73.7%) 10 (26.3%) 25.3%
III (42) 57.5 ± 8.8 30 (71.4%) 12 (28.6%) 28%
IV (7) 60 ± 6.3 5 (71.4%) 2 (28.6%) 4.7%
Total 117 (78%) 33 (22%) 150
P* 0.6 0.8
Tumor grade
Low
84 (56%)
55.6 ± 14.8 63 (53.8%) 21 (63.6%) 84 (56%)
High
66 (44%)
60 ± 10.6 54 (46.2%) 12 (36.4%) 66 (44%)
Total 117 (78%) 33 (22%) 150
c
I
s
t
S
T
sP** 0.3 
P* Anova test results revealed no significant correlation.
P** Student’s t-test results revealed no significant correlation.
relationship between two qualitative variables in a table with a cell
containing value less than five. The ROC curve (receiver operating
characteristic) was used to evaluate the sensitivity and specificity of
the quantitative diagnostic measures. The cut-off value of signifi-
cance was P  < 0.05.
Results
Patients  and  tumor  characteristicsPlease cite this article in press as: Ibrahim EA, et al. ETS-1 oncoprotei
carcinoma of the urinary bladder: An immunohistochemical study. Afr
The age of study cases ranged from 48–75 years with a mean value
of 57.5 ±  13.2 years. The majority of cases were males (78%) with
a male/female ratio of 3.5:1. Bilharizial infection was present in 39
c
T
s
Figure  1  (A) Entire normal urothelium showing positive ETS-1 staining. T
positive control (×200). (B) ETS-1 expression in low grade, non-invasive u
2 (×100). (c) ETS-1 expression in low grade, non-invasive urothelial carc
(D) ETS-1 Expression in low grade urothelial carcinoma with lamina propria
carcinoma with lamina propria invasion (pT1). ETS1 expression percentage
invasive urothelial carcinoma. ETS1 expression percentage is <10%, score 00.7
ases (26%). More than half of cases had early bladder cancer (stage
, 36%) and of low grade type (56%). There were no significant
tatistical correlation between both age and sex on one hand and
umor grade and stage on the other hand (Table 1).
tatistical  relationships
he microscopic examination of the immunohistochemically
tained slides revealed cytoplasmic and nuclear staining of the tumorn expression is decreased in aggressive papillary transitional cell
 J Urol (2016), http://dx.doi.org/10.1016/j.afju.2015.10.007
ells.
he entire normal (non-neoplastic) urothelium in the control group
howed positive ETS-1 staining (Fig. 1A).
he lymphocytes showed positive ETS-1 staining and served as internal
rothelial carcinoma (pTa). ETS1 expression percentage is 80%, score
inoma (pTa). ETS1 expression percentage is 80%, score 2 (×200).
 invasion (pT1) (×200). (E) ETS-1 Expression in high grade urothelial
 is 30%, score 1 (×200). (F) ETS-1 expression in high grade, muscle
 (Original magnification ×100).
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Table  2  Correlation between ETS-1 expression and tumor stage and grade.
Parameter ETS-1 P
0 1+ 2+
Control (24) 0 0 24
Tumor stage (N)
0 (9) 0 0 9 (100%) 0.001*
I (54) 9 (16.7%) 20 (37%) 25 (46.3%)
II (38) 15 (39.5%) 15 (39.5%) 8 (21%)
III (42) 10 (23.8%) 32 (76.2%) 0
IV (7) 5 (71.4%) 2 (28.6%) 0
Total 150 39 69 42
Tumor grade
Low
84 (56%)
21 (25%) 27 (32.1%) 36 (42.9%) 0.001**
High
66 (44%)
18 (27.3%) 42 (63.6%) 6 (9.1%)
Total 39 69 42
ing ET
ing E
T
e
(
i
0
a
g
(
W
s
<
a
E
h
7
D
T
h
s
t
a
g
o
U
b
9
t
i
w
H
t
fi
S
trol groups, with sample stratification into low and high tumor grades
as well as all the tumor stages. Furthermore, the semi-quantitative
assessment of the immunohistochemical stain results adds more* Highly significant correlation between control and tumor stage regard
** Highly significant correlation between control and tumor grade regard
here was a significant statistical correlation between ETS-1
xpression and tumor stage in comparison with the control group
P  = 0.001). The ETS-1 expression revealed down regulation with
ncreased tumor stage (Stages II, III and IV in comparison to stages
 and I). (Table 2, Fig. 1B–F). On the other hand, there was also
 significant correlation between ETS-1 expression and the tumor
rade with an observed down regulation with the high grade tumors
P  = 0.001) (Table 2, Fig. 1B–F).
ith quantitative assessment of the extent of immunohistochemical
taining and using ROC curve, it was found that ETS-1 expression
30% was associated with high grade tumors with 90.9% sensitivity
nd 50% specificity (Table 3, Fig. 2). Furthermore, it was found that
TS-1 expression <20% was associated with tumors that showed
igh invasive potential (muscle invasive, stage II or higher) with
5.8% sensitivity and 80.9% specificity (Table 3, Fig. 3).
iscussion
he current study showed down regulation of ETS-1 immuno-
istochemical expression with increased tumor stage with a high
ignificant statistical correlation (P  = 0.001). On the other hand,Please cite this article in press as: Ibrahim EA, et al. ETS-1 oncoprotei
carcinoma of the urinary bladder: An immunohistochemical study. Afr
here was also a significant correlation between ETS-1 expression
nd the tumor grade with an observed down regulation with the high
rade tumors (P  = 0.001). It means that decreased ETS-1 expression
ccurred with more aggressive tumors.
Table  3  Performance of ETS-1 immunohistochemical expression
in association with papillary transitional cell carcinoma of high grade
and stage.
Parameter High grade
tumors
Stages (II, III
and IV)
ETS-1 cut-off value ≤30 ≤20
Sensitivity 90.9% 75.9%
Specificity 50% 81%
Positive predictive value (PPV) 58.8% 84.6%
P 0.001 0.001 FhS-1 expression.
TS-1 expression.
sing ROC curve, it was found that ETS-1 expression <30% could
e used as a cut-off value for prediction of high grade tumors with
0.9% sensitivity and 50% specificity. Furthermore, it was found
hat ETS-1 expression <20% could be used as another cut-off value
n prediction of tumor with high invasive potential (muscle invasive)
ith 75.8% sensitivity and 80.9% specificity.
owever, the retrospective cross sectional nature of this study with
he lack of follow up information hinders the confirmation of its
ndings.
trengths of the study include the fair number of both study and con-n expression is decreased in aggressive papillary transitional cell
 J Urol (2016), http://dx.doi.org/10.1016/j.afju.2015.10.007
igure  2  ROC curve illustrating the performance of ETS-1 immuno-
istochemical expression with different tumor grades.
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J Clin Pathol 2000;114(50):719–25.Figure  3  ROC curve illustrating the performance of ETS-1 immuno-
histochemical expression with different tumor stages.
accurate evaluation. To the best of our knowledge this is the first
study to suggest cut-off values for prediction of tumors with high
grade and invasive potentials.
Here in our study, we observed that the majority of low-grade
and noninvasive urothelial carcinomas intensely expressed ETS-
1, whereas high-grade and invasive carcinomas showed a frequent
decrease of ETS-1 expression. This was in accordance with Sari
et al. [17] who found that ETS-1 expression showed a strong nega-
tive correlation with the tumor grade (P  < 0.001) and also found that
ETS-1 expression showed a strong negative correlation with the
tumor stage (P  < 0.001). The topographic distribution of the onco-
protein stain in both nucleus and cytoplasm is in agreement with
Nakayama et al. [11] who found similar results in colorectal carci-
noma, also the study of Ebel et al. [14] and Yamaguchi et al. [18]
where the stain revealed the same distribution in pulmonary and
endometrial adenocarcinoma respectively. This can be explained by
the oncoprotein overproduction which gives positive cytoplasmic
staining [10,18].
ETS-1 immunohistochemical expression can be used as an adjunct
prognostic tool with Hematoxylin and Eosin for better evaluation
of the papillary transitional cell carcinoma of the urinary bladder.
The evaluation of extent of immunohistochemical staining with use
of the suggested cut-off values may help in predicting the tumors
with higher invasive potentials. This may be valuable in making the
decision of either conservative or radical operations. However, fur-
ther researches with follow up data are needed to prove our results.
Furthermore, more studies using the same marker for non papillary
transitional cell carcinoma and those arising from the renal pelvis
or ureter are needed for comparison with our findings.
Conclusion
ETS-1 immunohistochemical expression showed down regulationPlease cite this article in press as: Ibrahim EA, et al. ETS-1 oncoprotei
carcinoma of the urinary bladder: An immunohistochemical study. Afr
with increased grade and stage of the primary urinary bladder pap-
illary transitional cell carcinoma. This may give a clue for more
understanding of this tumor carcinogenesis. In addition, it may be
[ PRESS
y bladder 5
sed as a prognostic marker especially for early urinary bladder
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